BirchBioMed

BirchBioMed Inc. is exclusively licenced by the University of British Columbia to develop anti-scarring drugs and autoimmune therapies based on FS2

[BirchBioMed @BirchBioMed]

Sensus Healthcare Launches Collaboration with BirchBioMed https://t.co/OPWzFlStfX

[UBC UILO @techtransfer]

Times Square spotlight shines on @UBC spin-off company @birchbiomed's anti-scarring drug developed at @VCHResearch

[BirchBioMed @BirchBioMed]

@BioPrecision
Look forward to talking. Can you DM us an email address?

[BirchBioMed @BirchBioMed]

BirchBioMed in New York City! Dr. Ghahary and Dr. Hartwell on the sign in Times Square #clinicaltrials #AntiScarring

[CNWBiotech @CNWBiotech]

.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug https://t.co/VO3zhaUra5

[CNWHealthcare @CNWHealthcare]

.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug https://t.co/BHaLmYJdeq

[CNWNews @CNWNews]

.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug https://t.co/CPpzNNiCB3

[BirchBioMed @BirchBioMed]

BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug https://t.co/o546YWMaIi

[Mark Miller @Mark_S_Miller]

BirchBioMed's ground-breaking therapeutics in the news @BirchBioMed #scarring #autoimmune #biomedical https://t.co/7F6yNeK95O

[BirchBioMed @BirchBioMed]

BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug https://t.co/W35ukoEOXF